Schedule a Meeting
Get a SampleJanuary 2025
The global cancer biopsy market size is calculated at USD 36.55 billion in 2025 and is forecasted to reach around USD 172.29 billion by 2034, accelerating at a CAGR of 18.80% from 2025 to 2034. The North America market size surpassed USD 14.46 billion in 2024 and is expanding at a CAGR of 18.80% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global cancer biopsy market size accounted for USD 30.77 billion in 2024 and is predicted to increase from USD 36.55 billion in 2025 to approximately USD 172.29 billion by 2034, expanding at a CAGR of 18.80% from 2025 to 2034.
The U.S. cancer biopsy market size was exhibited at USD 8.87 billion in 2024 and is projected to be worth around USD 50.60 billion by 2034, growing at a CAGR of 19.02% from 2025 to 2034.
North America dominated the cancer biopsy market in 2024. The North America region is expected to maintain its lead during the projected period, with the U.S. contributing significantly to regional revenue. Furthermore, distributors and manufacturers in this region are working to sale and manufacture unique kits that are well-suited for quick diagnostic applications.
Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The number of lung cancer cases detected in Asia has increased due to rising awareness among patients and healthcare professionals.
The removal of tissue for the purpose of examining it for disease is known as a biopsy. Any region of the body can be used to collect tissue samples. Biopsies can be done in a variety of methods. Some biopsies entail taking a little bit of tissue with a needle, while others entail surgically removing a suspected lump or nodule. The imaging tests like MRIs and CT scans can assist detect lumps or abnormal tissue, but they cannot distinguish the difference between cancerous and non-cancerous cells. The only approach to diagnose most malignancies is to take a biopsy and collect cells for further analysis.
The growing elderly population, together with the rising prevalence of cancer indications, is likely to drive the cancer biopsy market expansion. Furthermore, the introduction of liquid biopsy procedures is projected to boost the cancer biopsy market forward. In the field of oncology diagnostics, many procedures such as skin, needle, bone marrow, endoscopic, and surgical biopsies are used on a large scale. The needles biopsies are regarded a favored tool for early detection of patients among these techniques. However, benefits of fine needle aspiration needle biopsies, such as reduced invasion and faster results, have the cancer biopsy market expansion.
The liquid biopsy for cancer diagnosis, prognosis, screening, and treatment has increased competition and capabilities in the cancer biopsy market significantly. The key market players are taking significant steps to enter the cancer biopsy market and are conducting liquid biopsies, which are projected to drive the cancer biopsy market’s growth in clinical settings. The liquid biopsy is being utilized to diagnose advanced cancer in individuals who are unable to undergo a tissue biopsy.
The liquid biopsy can also be used to determine targeted therapy or clinical trial eligibility for patients for whom tissue-based testing is not appropriate or available. The liquid biopsy provides oncologists with real-time information about a tumor and is a quick, minimally invasive, and cost-effective diagnostic. These tests have the potential to reveal residual tumor cells, early recurrence diagnosis, and treatment efficacy.
While the issues connected with cancer biopsy pose significant obstacles for technology vendors, laboratories, and clinicians, patients who want to avoid the genuine hazards, potential pain, and high costs associated with tissue biopsy have a strong demand for liquid biopsy. Furthermore, the ability to track treatments and detect disorder early, as well as collect data across the tumor, gives patients a better chance of receiving appropriately targeted therapy.
In terms of instruments, kits, and consumables, cancer biopsy has seen a number of technological advancements. The development of effective products associated with biopsies is critical as liquid biopsy becomes a multimodal tool of diagnosis in the field of clinical oncology. Despite the fact that existing instruments are widely utilized, they have a number of flaws. The introduction of new technologies, on the other hand, is predicted to dramatically enhance the need for instruments in the coming years. Several new companies are concentrating on developing equipment that can improve endoscopy-based biopsies.
| Report Coverage | Details |
| Market Size in 2025 | USD 36.55 Billion |
| Market Size in 2024 | USD 30.77 Billion |
| Market Size by 2034 | USD 172.29 Billion |
| Growth Rate from 2025 to 2034 | CAGR of 18.80% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Type, Product, Application, and, Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
The tissue biopsy had the highest revenue share in 2024. It is still widely used in biopsies and is widely used across a variety of cancer diagnosis applications. This is due to the rigorous research operations testing its safety and efficacy, which have helped to the expansion of this segment.
The liquid biopsy segment is fastest growing segment of the cancer biopsy market in 2024. In recent years, there has been an increase in physician preference for liquid biopsy, which is bolstered by its capacity to provide disease assessments from both the primary and distant tumor locations. This method is used in personalized medicine treatment, where tumor makers are sampled regularly to adjust the treatment based on the patient’s response.
The kits and consumables segment dominated the cancer biopsy market in 2024. The segment’s expansion has been aided significantly by large investments made by major market players in the industry.
The instruments segment, on the other hand, is predicted to develop at a rapid rate over the projection period. The rise of the market is related to an increase in the number of patients around the world who require precise, efficient, and quick tools and kits.
In 2024, the breast cancer segment dominated the cancer biopsy market. The growing number of patients suspected of having breast cancer undergoes microscopic study of breast tissue, which is required for obtaining a clear diagnosis, as well as determining the stage and type.
The prostate cancer segment, on the other hand, is predicted to develop at the quickest rate in the future years. The liquid biopsies based on circulating tumor cells can track the minimal residual disease in non-metastatic prostate cancer patients, as well as the follow up examinations, to provide independent prognostic insights.
By Product
By Type
By Application
By Regions
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
January 2025
April 2025
September 2024
October 2024